Article
Chemistry, Multidisciplinary
Chaemin Lim, Duhyeong Hwang, Mostafa Yazdimamaghani, Hannah Marie Atkins, Hyesun Hyun, Yuseon Shin, Jacob D. Ramsey, Patrick D. Raedler, Kevin R. Mott, Charles M. Perou, Marina Sokolsky-Papkov, Alexander V. Kabanov
Summary: The presence of immunosuppressive immune cells in tumors is a barrier to therapeutic immune responses. This study used polymeric micelles to enhance the adaptive T cell immunity against triple-negative breast cancers (TNBCs) by delivering the small molecule drugs paclitaxel (PTX) and CSF1R inhibitor PLX3397. The combination therapy repolarized the immunosuppressive tumor microenvironment, resulting in inhibited primary tumor growth and metastasis.
Article
Oncology
Ran Ding, Yuhan Wang, Jinyan Fan, Ziyue Tian, Shuang Wang, Xiujuan Qin, Wei Su, Yanbo Wang
Summary: This study analyzed RNA-seq data from 303 TNBC samples and identified a significant T cell depletion signature in the TNBC tumor microenvironment. It also found that some TNBC patients exhibit an immunosuppressive state and have a poor prognosis and resistance to ICB treatment. These findings can be used to construct prognostic models and study the immune mechanisms within the tumor microenvironment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Mohammed H. Qusa, Khaldoun S. Abdelwahed, Abu Bakar Siddique, Khalid A. El Sayed
Summary: The study investigates the potential of OC-X formulation in suppressing heterogeneous TNBC models and offers preliminary insights into the gene-level therapeutic mechanisms.
Article
Oncology
Yangyang Guo, Kenan Cen, Shi Yang, Yifeng Mai, Kai Hong
Summary: In this study, we discovered IRGs clusters and developed a signature consisting of four genes using LASSO method, which was highly correlated with the prognoses of TNBC patients. Compared to other individual predictors, the IRGs signature showed remarkable superiority. Additionally, the low-risk group had elevated ImmuneScores and significant differences in immune cell infiltration and expression of immune checkpoints compared to the high-risk group.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Hui Lyu, Fei Shen, Sanbao Ruan, Congcong Tan, Jundong Zhou, Ann D. Thor, Bolin Liu
Summary: Increased expression of HER3 is associated with poor prognosis in TNBC. Inhibition of HER3 expression inhibits TNBC cell proliferation and tumor growth. The anti-HER3 monoclonal antibody (mAb) 4A7 enhances the efficacy of gefitinib or paclitaxel in TNBC.
CANCER CELL INTERNATIONAL
(2023)
Article
Chemistry, Medicinal
Tianyu Chen, Hui Chen, Yichun Jiang, Qi Yan, Shuling Zheng, Min Wu
Summary: In this study, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel were developed and demonstrated to have enhanced anticancer activity against triple-negative breast cancer (TNBC). The liposomes showed improved drug delivery to mitochondria and induced mitochondria-mediated apoptosis. In a mouse model, the liposomes also exhibited favorable antitumor activity with targeted tumor and mitochondria delivery, without obvious systemic toxicity.
Article
Genetics & Heredity
Kankan Zhao, Yuan Zheng, Wenliang Lu, Bo Chen
Summary: In this study, the roles of ubiquitination-related genes (URGs) in triple-negative breast cancer (TNBC) were explored. An 11-URG predictive model was constructed and showed good performance in predicting the overall survival of TNBC patients. Immune-related characteristics were higher in the low-risk group. These findings contribute to a better understanding of molecular mechanisms and the development of novel therapeutic targets for TNBC.
FRONTIERS IN GENETICS
(2023)
Article
Biochemistry & Molecular Biology
T. Dhanushkumar, Balu Kamaraj, Karthick Vasudevan, Mohanraj Gopikrishnan, K. R. Dasegowda, Majji Rambabu, C. George Priya Doss
Summary: This study utilizes immunoinformatics and reverse vaccinology to develop an in-silico vaccine for TNBC. Four vaccines were designed using the TRIM25 molecule and docking experiments showed that vaccine-3 had the highest affinity with immune receptors. Molecular dynamics results demonstrated that vaccine-3 had higher binding affinity and stability compared to vaccine-2 complexes. This study presents a promising preventive strategy for TNBC and further research is needed to evaluate its efficacy in preclinical settings.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Oncology
Maolin Yi, Chengcheng Peng, Bingxiang Xia, Lin Gan
Summary: This study demonstrates the overexpression of CXCL8 in TNBC tissues and cells, and reveals its negative regulation on the sensitivity of TNBC cells to paclitaxel. CXCL8 is found to decrease cell apoptosis in paclitaxel-resistant TNBC cells.
CLINICAL BREAST CANCER
(2022)
Article
Oncology
Lori J. Goldstein, Mauro Mansutti, Christelle Levy, Jenny C. Chang, Stephanie Henry, Isaura Fernandez-Perez, Jana Prausova, Elzbieta Staroslawska, Giuseppe Viale, Beth Butler, Susan McCanna, Pier Adelchi Ruffini, Max S. Wicha, Anne F. Schott
Summary: The addition of reparixin to first-line therapy with paclitaxel did not significantly prolong progression-free survival in metastatic triple-negative breast cancer patients.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Biochemistry & Molecular Biology
Shan-Ju Yeh, Bo-Jie Hsu, Bor-Sen Chen
Summary: Triple-negative breast cancer (TNBC) is a subtype with poor prognosis, and understanding the molecular mechanisms is challenging due to cascade signaling pathways and genetic regulations. A systematic design using systems biology approaches identified potential multi-molecule drugs for both TNBC and non-TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Nicoletta Cordani, Daniela Lisini, Valentina Cocce, Giuseppe Paglia, Ramona Meanti, Maria Grazia Cerrito, Pietro Tettamanti, Luca Bonaffini, Francesca Paino, Giulio Alessandri, Angela Marcianti, Aldo Gianni, Chiara Villa, Mario Mauri, Luca Mologni, Antonio Torsello, Augusto Pessina, Marina Elena Cazzaniga
Summary: Triple-negative breast cancer is a highly aggressive disease with a poor prognosis. While paclitaxel is effective, it can cause peripheral neuropathy as a dose-limiting toxicity. Mesenchymal stromal cells loaded with paclitaxel show stronger inhibitory effects on survival, migration, and tumorigenicity in TNBC cell lines compared to free paclitaxel, suggesting a potential new drug delivery strategy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Zhaoping Qiu, Weijie Guo, Bo Dong, Yu Wang, Pan Deng, Chi Wang, Jinpeng Liu, Qing Zhang, Rudolf Grosschedl, Zhiyong Yu, Jiong Deng, Yadi Wu
Summary: EBF1 is highly expressed in TNBC and plays a crucial role in tumorigenicity and progression; By forming a transcriptional complex with HIF1 alpha, EBF1 regulates cell mitophagy and prevents cell death; Targeting EBF1 pathway may offer alternative treatment strategies for TNBC.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Biochemistry & Molecular Biology
Linlin Lu, Zihe Niu, Zhujun Chao, Cuiping Fu, Kai Chen, Yaqin Shi
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and standard treatment options are limited. Antibody-drug conjugates (ADCs) have shown promise in clinical studies, but resistance is a challenge. Combining ADCs with other treatment strategies may provide a more effective approach.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sudipta Roy, Timothy D. Whitehead, Shunqiang Li, Foluso O. Ademuyiwa, Richard L. Wahl, Farrokh Dehdashti, Kooresh I. Shoghi
Summary: The study aimed to optimize radiomic features using patient-derived tumor xenografts (PDX) in predicting therapy response in TNBC, and to implement these features in a co-clinical study using machine learning algorithms to predict therapy response.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
E. P. Mamounas, M. Untch, M. S. Mano, C-S Huang, C. E. Geyer, G. von Minckwitz, N. Wolmark, X. Pivot, S. Kuemmel, M. P. DiGiovanna, B. Kaufman, G. Kunz, A. K. Conlin, J. C. Alcedo, T. Kuehn, I Wapnir, A. Fontana, J. Hackmann, J. Polikoff, M. Saghatchian, A. Brufsky, Y. Yang, M. Zimovjanova, T. Boulet, H. Liu, D. Tesarowski, L. H. Lam, C. Song, M. Smitt, S. Loibl
Summary: T-DM1 shows good safety and efficacy in patients with HER2-positive EBC, benefiting different subgroups without increasing the risk of central nervous system recurrence.
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
M. Graeser, O. Gluz, C. Biehl, D. Ulbrich-Gebauer, J. Palatty, M. Christgen, S. Kuemmel, E-M. Grischke, D. Augustin, M. Braun, J. Potenberg, R. Wuerstlein, C. Eulenburg, R. Kates, C. Kolberg-Liedtke, F. Feuerhake, H. Kreipe, U. Nitz, N. Harbeck
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Gebra Cuyun Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M. Tolaney
Summary: In advanced breast cancer patients with HR+/HER2-, prognostic factors such as negative progesterone receptor status, higher tumor grade, higher CTC count, and higher Ki67 level are strongly associated with worse overall survival. Factors like CTC count and number and sites of metastases are also strongly associated with progression-free survival.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Surgery
Christoph Wallner, Vanessa Dahlmann, Paolo Montemurro, Sherko Kuemmel, Mattea Reinisch, Marius Drysch, Sonja Verena Schmidt, Felix Reinkemeier, Julika Huber, Johannes Maximilian Wagner, Alexander Sogorski, Mehran Dadras, Maxi von Glinski, Marcus Lehnhardt, Bjoern Behr
Summary: This study utilized lifelike morphed 3D-generated female models in an online survey with 1049 participants to investigate breast preferences. The results showed a 55:45 upper-pole-to-lower-pole ratio preference, gender-specific differences in preferred breast size, and a preference for a 30 mm areola size. The use of anatomically accurate computer-generated 3D models in this study provided more reliable and comparable results, shedding light on unexpected insights into preferred breast attributes among the population.
AESTHETIC PLASTIC SURGERY
(2022)
Article
Oncology
Walter P. Weber, Zoltan Matrai, Stefanie Hayoz, Christoph Tausch, Guido Henke, Daniel R. Zwahlen, Guenther Gruber, Frank Zimmermann, Stefanie Seiler, Charlotte Maddox, Thomas Ruhstaller, Simone Muenst, Markus Ackerknecht, Sherko Kuemmel, Vesna Bjelic-Radisic, Christian Kurzeder, Mihaly Ujhelyi, Conny Vrieling, Rok Satler, Inna Meyer, Charles Becciolini, Susanne Bucher, Colin Simonson, Peter M. Fehr, Natalie Gabriel, Robert Maraz, Dimitri Sarlos, Konstantin J. Dedes, Cornelia Leo, Gilles Berclaz, Peter Dubsky, Ruth Exner, Hisham Fansa, Christopher Hager, Klaus Reisenberger, Christian F. Singer, Roland Reitsamer, Mattea Reinisch, Jelena Winkler, Giang Thanh Lam, Mathias K. Fehr, Tatiana Naydina, Magdalena Kohlik, Karine Clerc, Valerijus Ostapenko, Florian Fitzal, Rahel Nussbaumer, Nadia Maggi, Alexandra Schulz, Pagona Markellou, Loic Lelievre, Daniel Egle, Joerg Heil, Michael Knauer
Summary: Tailored axillary surgery (TAS) is an effective method to reduce tumor load in the axilla of patients with clinically node-positive breast cancer, with a much less radical approach compared to axillary lymph node dissection (ALND).
Article
Oncology
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Ozguroglu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Summary: This phase II study aimed to evaluate the efficacy of lacnotuzumab added to gemcitabine plus carboplatin in patients with advanced triple-negative breast cancer. The results showed that lacnotuzumab + gem-carbo had comparable antitumor activity to gem-carbo alone, but with slightly poorer tolerability.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Andre Pfob, Chris Sidey-Gibbons, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, Sherko Kuemmel, Toralf Reimer, Markus Hahn, Marc Thill, Jens-Uwe Blohmer, John Hackmann, Wolfram Malter, Inga Bekes, Kay Friedrichs, Sebastian Wojcinski, Sylvie Joos, Stefan Paepke, Tom Degenhardt, Joachim Rom, Achim Rody, Marion van Mackelenbergh, Maggie Banys-Paluchowski, Regina Grosse, Mattea Reinisch, Maria Karsten, Michael Golatta, Joerg Heil
Summary: Neoadjuvant systemic treatment is effective for breast cancer patients, but current nonsurgical methods cannot accurately identify patients without residual cancer. We developed an intelligent vacuum-assisted biopsy approach using machine learning algorithm, which can reliably exclude residual cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Pathology
Matthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos, Stephan Bartels, Mieke R. Van Bockstal, Martin Bredt, Maria Jose Brito, Henriette Christgen, Cecile Colpaert, Balint Cserni, Gabor Cserni, Maximilian E. Daemmrich, Raihanatou Danebrock, Franceska Dedeurwaerdere, Carolien H. M. van Deurzen, Ramona Erber, Christine Fathke, Henning Feist, Maryse Fiche, Claudia Aura Gonzalez, Natalie D. ter Hoeve, Loes Kooreman, Till Krech, Glen Kristiansen, Janina Kulka, Florian Laenger, Marcel Lafos, Ulrich Lehmann, Maria Dolores Martin-Martinez, Sophie Mueller, Enrico Pelz, Mieke Raap, Alberto Ravarino, Tanja Reineke-Plaass, Nora Schaumann, Anne-Marie Schelfhout, Maxim De Schepper, Jerome Schlue, Koen Van de Vijver, Wim Waelput, Axel Wellmann, Monika Graeser, Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck, Christine Desmedt, Giuseppe Floris, Patrick W. B. Derksen, Paul J. van Diest, Anne Vincent-Salomon, Hans Kreipe
Summary: Subtyping of breast cancer as ILC achieves almost perfect agreement with a pre-defined reference standard if supported by E-cadherin IHC. CDH1 missense mutations, E- to P-cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2022)
Correction
Oncology
U. A. D. Nitz, O. Gluz, M. Christgen, E. -M. Grischke, D. Augustin, S. Kuemmel, M. Braun, J. Potenberg, A. Kohls, K. Krauss, A. Stefek, C. Schumacher, H. Forstbauer, T. Reimer, H. Fischer, C. Liedtke, R. Wuerstlein, J. Schumacher, R. Kates, H. Kreipe, N. Harbeck, WSG-ADAPT Investigators
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Ulrike A. Nitz, Oleg Gluz, Sherko Kuemmel, Matthias Christgen, Michael Braun, Bahriye Aktas, Kerstin Luedtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Maren Darsow, Katja Krauss, Benno Nuding, Marc Thill, Jochem Potenberg, Christoph Uleer, Mathias Warm, Hans Holger Fischer, Wolfram Malter, Michael Hauptmann, Ronald E. Kates, Monika Graeser, Rachel Wuerstlein, Steven Shak, Frederick Baehner, Hans H. Kreipe, Nadia Harbeck
Summary: The WSG-ADAPT-HR+/HER2- study demonstrates the feasibility of guiding systemic treatment for breast cancer using both the recurrence score (RS) and endocrine therapy (ET) response, and avoids the use of chemotherapy in pre- and postmenopausal patients with <= 3 involved lymph nodes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, Erika Hamilton, Nadia Harbeck, Jennifer Klemp, Michael Knauer, Sherko Kuemmel, Reshma Mahtani, Lee Schwartzberg, Cynthia Villarreal-Garza, Antonio Wolff
Summary: This article summarizes the key results of an expert panel discussion on optimizing ovarian function suppression for premenopausal women with HR+, HER2- early breast cancer. The panel suggests that combining chemotherapy with ovarian function suppression may result in better treatment outcomes and avoid adverse effects associated with adjuvant chemotherapy.
Article
Oncology
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva -Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Summary: This study identified associations of biological signatures and stromal tumor-infiltrating lymphocytes with pathological complete response and survival in HER2+/HR- early breast cancer. ERBB2 and estrogen receptor signaling were favorable while PTEN was unfavorable for pCR. Gene signatures related to immune response and ER signaling were favorable for invasive disease-free survival.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Nadia Harbeck, Ulrike A. Nitz, Matthias Christgen, Sherko Kuemmel, Michael Braun, Claudia Schumacher, Jochem Potenberg, Joke Tio, Bahriye Aktas, Helmut Forstbauer, Eva-Maria Grischke, Iris Scheffen, Wolfram Malter, Raquel von Schumann, Marianne Just, Christine zu Eulenburg, Claudia Biehl, Cornelia Kolberg-Liedtke, Regula Deurloo, Sanne de Haas, Katarzyna Jozwiak, Michael Hauptmann, Ronald Kates, Monika Graeser, Rachel Wuerstlein, Hans H. Kreipe, Oleg Gluz
Summary: The WSG-ADAPT-TP trial demonstrated that pathological complete response (pCR) after 12 weeks of chemotherapy-free de-escalated neoadjuvant therapy was associated with excellent survival in hormone receptor-positive/human epidermal growth factor receptor 2-positive early breast cancer (HR+/HER2+ EBC) without further adjuvant chemotherapy (ACT). Patients with pCR had similar 5-year invasive disease-free survival (iDFS) rates whether or not they received ACT. Patient selection based on biomarkers or molecular subtypes may improve efficacy of HER2-targeted approaches without systemic chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Christopher Herzog, Lale Umutlu, Alex Frydrychowicz, Dorothea Rjosk-Dendorfer, Rachel Wuerstlein, Ralph Culemann, Christine Eulenburg, Jascha Adams, Henrik Nitzsche, Anna Prange, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Nadia Harbeck, Christiane K. Kuhl, Ulrike Nitz
Summary: This study evaluated the accuracy of predicting histological tumor size by post-neoadjuvant therapy ultrasound and MRI in different breast cancer subtypes. The findings suggest that in HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely to underestimate tumor size compared to ultrasound.
BREAST CANCER RESEARCH
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
